» Articles » PMID: 20190201

Case Series: Acute Tumor Lysis Syndrome in Mutator Mice with Disseminated Lymphoblastic Lymphoma

Overview
Journal Toxicol Pathol
Publisher Sage Publications
Date 2010 Mar 2
PMID 20190201
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Acute tumor lysis syndrome (ATLS) is characterized by severe metabolic abnormalities and organ dysfunction resulting from rapid destruction of neoplastic cells. Metabolic disturbances are thought to be the primary cause of clinical ATLS symptoms, which include renal dysfunction, seizures, and cardiac arrhythmias. The histopathologic lesions associated with organ dysfunction are largely unknown because of the low rate of mortality of ATLS in humans and the few cases of ATLS identified in laboratory animals. Here, we describe histologic, immunohistochemical, and electron microscopic analyses of thirty-one ATLS cases from a cohort of 499 mice that are prone to spontaneous lymphoblastic lymphoma owing to genetic defects in DNA replication fidelity. Seventy-three percent of our cohort died with lymphoblastic lymphoma, and 8% of affected mice died with diffuse microthromboemboli consistent with ATLS. Mice with ATLS had a high spontaneous mortality rate (>50%), a large tumor burden with disseminated disease, and evidence of leukemia. Blood vessels in the lung, kidney, and other organs were occluded by microthromboemboli composed of chromatin, cellular debris, fibrin, platelets, and entrapped erythrocytes and malignant cells. This case series suggests that ATLS can occur at high frequency in mice with disseminated lymphoblastic lymphoma and leads to a high rate of spontaneous death from microthromboemboli.

Citing Articles

Serum phosphate level and its kinetic as an early marker of acute kidney injury in tumor lysis syndrome.

Lemerle M, Schmidt A, Thepot-Seegers V, Kouatchet A, Moal V, Raimbault M J Nephrol. 2022; 35(6):1627-1636.

PMID: 35107777 DOI: 10.1007/s40620-022-01263-7.


Cotargeting BCL-2 and MCL-1 in high-risk B-ALL.

Moujalled D, Hanna D, Hediyeh-Zadeh S, Pomilio G, Brown L, Litalien V Blood Adv. 2020; 4(12):2762-2767.

PMID: 32569380 PMC: 7322969. DOI: 10.1182/bloodadvances.2019001416.


POLE proofreading defects: Contributions to mutagenesis and cancer.

Park V, Pursell Z DNA Repair (Amst). 2019; 76:50-59.

PMID: 30818169 PMC: 6467506. DOI: 10.1016/j.dnarep.2019.02.007.


Explosive mutation accumulation triggered by heterozygous human Pol ε proofreading-deficiency is driven by suppression of mismatch repair.

Hodel K, De Borja R, Henninger E, Campbell B, Ungerleider N, Light N Elife. 2018; 7.

PMID: 29488881 PMC: 5829921. DOI: 10.7554/eLife.32692.


T-cell Immunotherapies and the Role of Nonclinical Assessment: The Balance between Efficacy and Pathology.

Sharpe M Toxicol Pathol. 2018; 46(2):131-146.

PMID: 29471776 PMC: 5843031. DOI: 10.1177/0192623317752101.